SEC Form EFFECT filed by Alpha Cognition Inc.
$ACOG
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 8, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | July 8, 2025 4:00 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/18/2025 | $20.00 | Buy | H.C. Wainwright |
10-Q - Alpha Cognition Inc. (0001655923) (Filer)
424B3 - Alpha Cognition Inc. (0001655923) (Filer)
S-3 - Alpha Cognition Inc. (0001655923) (Filer)
Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.
Conference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6 - Participant
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" [ACI], or the "Company"), a biopharmaceutical company developing novel therapies for debilitating neurodegenerative disorders, today announced China Medical System Holdings Limited (CMS) New Drug Application (NDA) for ZUNVEYL has been accepted by the National Medical Products Administration of China (NMPA) for review for the treatment of mild-to-moderate Alzheimer's dementia. "We are pleased to announce the NMPA acceptance of the ZUNVEYL New Drug Application, marking a significant milestone in our mission to bring innovative treatments to patients in need," said Michael McFadden, Chief Executive Officer of Alpha Cognition. "This accept
4 - Alpha Cognition Inc. (0001655923) (Issuer)
4 - Alpha Cognition Inc. (0001655923) (Issuer)
3 - Alpha Cognition Inc. (0001655923) (Issuer)
H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00
Key Highlights ZUNVEYL Launch Momentum: Completed the first quarter of ZUNVEYL commercialization, achieving approximately $2 million in net product revenues year-to-date. Advancing ALPHA-1062: Completed pre-clinical Bomb Blast study in collaboration with the U.S. Department of Defense and the Seattle Institute of Biomedical and Clinical Research. Strong Balance Sheet: Cash and cash equivalents of $39.4 million as of June 30, 2025, supporting an estimated cash runway of approximately two years at the current utilization rate. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition" or the "Company") today announced its financial results for the second quarter ended June 30, 2025.
Conference Call Scheduled for August 14, 2025 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will release financial results for the second quarter on August 14, 2025 after close of market. Following the release, management will host a conference call to review financial and operating results. Conference Call Information: To participate in the conference call, please use the dial-in information below: Participant Listening: 1-877-407-9039 or 1-201-689-8470 or https://callme.viavid.com/viavid/?callme=true&passcode=13752398&h=true&info=company&r=true&B=6 - Participant
Launched ZUNVEYL (benzgalantamine) to US market on March 17, 2025 Secured business development licensing revenues of $2.6M for partnership with CMS Pharma Cash and cash equivalents of $45.5 million as of March 31, 2025, compared to $48.6 million as of December 31, 2024. At current cash utilization rates, the Company expects a cash runway of approximately two years. Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company") today announced its financial results for the first quarter ended March 31, 2025. "We closed the quarter on a strong note, launching ZUNVEYL® to the long-term care market," said Michael McFadden, Chief Executive Officer. "We feel that the company is
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.
Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic